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The preference of MuLV for the selection of tRNAPro as a replication primer was investigated by altering the primer-binding site (PBS) to
be complementary to tRNALys,3. MuLV-based vectors with a PBS complementary to tRNALys,3 were found to be approximately 2-fold less
infectious than vectors with the wild-type PBS complementary to tRNAPro. MuLV with a PBS complementary to tRNALys,3 was replication
competent and maintained the PBS during early stages of in vitro culture. Upon extended culture, PBS were isolated which were
complementary to tRNAArg. A second MuLV was generated in which the region upstream of the PBS which is predicted to form an RNA
stem loop structure was altered so that the nucleotide sequence within the loop would be complementary to the anticodon of tRNALys,3. The
virus with both the U5 and PBS complementary to tRNALys,3 was also replication competent. Upon extended in vitro culture though, this
virus reverted to utilize tRNALys1,2. Analysis of the infectivity and replication of the wild-type and mutant viruses revealed that tRNAPro was
the preferred tRNA for high-level replication. Viruses with a PBS complementary to tRNAArg or tRNALy1,2 replicated at levels approximately
30% and 10% as effective as the wild-type virus, while virus with a PBS complementary to tRNALys,3 had the slowest replication kinetics and
least infectivity. Comparison of the virion tRNA content of the wild-type and mutant viruses revealed similar ratios with respect to levels of
tRNAPro, tRNAArg and tRNALys. Modeling of the U5-PBS region revealed that the predicted RNA structure for the virus that selected
tRNAArg was more similar to the wild type virus that uses tRNAPro than the virus which use tRNALys1,2 or tRNALys,3; the virus that uses
tRNALys,3 had the most profound disruption in the predicted RNA structure. The results of these studies demonstrate that MuLV has evolved
to preferentially select tRNAPro for high-level replication and are discussed with respect to common features of the primer selection process
between MuLV and other retroviruses.
D 2005 Elsevier Inc. All rights reserved.
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A distinguishing feature of retrovirus replication is the
process by which the single-stranded RNA genome is
converted to the DNA form followed by integration into
the host cell chromosome. The process termed reverse
transcription is catalyzed by a viral encoded RNA dependent
DNA polymerase (reverse transcriptase) (Baltimore, 1970;
Temin and Mizutani, 1970). Reverse transcription initiates0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.12.033
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E-mail address: caseym@uab.edu (C.D. Morrow).near the 5V end of the viral genome at a sequence which is
complementary to the 3V terminal nucleotides of a host cell
tRNA molecule which is used as the primer for reverse
transcription (Panet and Berliner, 1978; Peters and Dahlberg,
1979; Temin, 1981). The reverse transcriptase extends from
the bound tRNA and through a series of intricate trans-
location events producing a complete copy of the viral
genome, which is then the substrate for integration into the
host cell chromosome (Gilboa et al., 1979; Taylor and Hsu,
1980; Varmus and Swanstrom, 1982).
The tRNA selected by different retroviruses for use as a
primer for reverse transcription varies between different05) 337–348
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from the intracellular milieu as the primer for reverse
transcription (Harada et al., 1979). In contrast, Lentiviruses,
such as HIV and SIV preferentially select tRNALys,3, while
avian leukosis virus (ALV) preferentially selects tRNATrp as
the primer for reverse transcription (Harada et al., 1975;
Mak and Kleiman, 1997; Marquet et al., 1995). The process
by which the tRNA is selected from the intracellular milieu
by retroviruses is still unresolved. Previous studies using
HIV and ALV have demonstrated that alteration of the PBS
to be complementary to a non-wild-type tRNA allows the
virus to utilize these tRNAs for reverse transcription (Das et
al., 1995; Li et al., 1994; Wakefield et al., 1995; Whitcomb
et al., 1995). However, the extended growth of these viruses
in tissue culture results in the reversion back to the use of
the wild-type tRNA. For the most part, this occurs as a result
of inappropriate priming on the mutant PBS by the wild-
type tRNA, and during plus-strand synthesis, the reverse
transcriptase recopies the wild-type tRNA to generate a
mismatched PBS that is repaired upon integration into the
host cell chromosome. What dictates which tRNAs are
preferred for initiation of reverse transcription is not entirely
clear. With respect to HIV, alteration of a region upstream of
the PBS that is predicted to interact with the anticodon loop
of tRNALys,3 can have profound effects on the subsequent
capacity of the virus to utilize alternative tRNA primers for
initiation of reverse transcription. Previous studies have
shown that HIV-1 can be generated which stably utilize
tRNAHis, tRNAMet, tRNALys1,2, or tRNAGlu by alteration of
both the PBS as well as the region upstream to be
complementary to the 3V terminal nucleotides and anticodon
loop, respectively, of these tRNAs (Dupuy et al., 2003;
Kang et al., 1997, 1999; Wakefield et al., 1996). However,
not all combinations work in that similar mutations of the
PBS and upstream regions to be complementary to tRNAPro,
tRNATrp, and tRNAIle did not result in HIV that could stably
utilize these tRNAs for initiation of reverse transcription
(Kang et al., 1996).
Early on, an MuLV was identified in which the PBS was
found to be complementary to tRNAGln (Colicelli and Goff,
1986a). Similar to HIV and ALV, previous studies have
shown that alteration of the PBS of MuLV from comple-
mentarity with tRNAPro to alternative tRNAs has resulted in
a virus that can utilize this tRNA for initiation of reverse
transcription. MuLV have been described in which the PBS
has been genetically altered to correspond to different
tRNAs, including a synthetic tRNA (Lund et al., 1993,
1997, 2000a, 2000b). In each case, the virus was viable as
evidenced by the capacity to undergo a single round of
replication. A previous study also noted that MuLV in which
the PBS was changed to be complementary to tRNALys,3
was viable and maintained this PBS following in vitro
culture (Lund et al., 1999). This result led to the suggestion
that complementarity with the PBS is the determinant for
selection of the tRNA primer to a MuLV (Fu et al., 1997;
Lund et al., 1993).In a recent study, we found that MuLV vectors in which
the PBS was complementary to yeast tRNAPhe evolved to
use tRNAGln even in the presence of yeast tRNAPhe
(Palmer and Morrow, 2004). In the current study, we
sought to further explore the primer selection process by
MuLV. Based on these earlier studies, we constructed an
infectious MuLV genome in which the PBS has been
altered to be complementary to tRNALys,3. In addition, we
modified a region upstream of the PBS predicted by mfold
to be in a RNA stem loop such that the nucleotides would
now be complementary to the anticodon region of
tRNALys,3 (Zuker, 2003). We analyzed the replication and
stability of the PBS of these mutant viruses following
extended in vitro culture. In contrast to previous findings,
we found that the MuLV with the PBS complementary to
tRNALys,3 changed to use a new, unexpected tRNA
(tRNAArg). The inclusion of nucleotides complementary
to the anticodon of tRNALys,3 as well as a PBS
complementary to tRNALys,3 resulted in a virus that also
was unstable and changed to utilize tRNALys1,2. The results
of these studies support the idea that additional influences
other than complementarity with the PBS are important for
primer selection by MuLV.Results
Single-cycle replication of MuLV with a PBS
complementary to tRNALys,3
In our first experiment, we changed the PBS of the
retroviral vector pLEGFP-C1 from its native complemen-
tarity to tRNAPro to be complementary to tRNALys,3 (Fig.
1A), the tRNA used by HIV-1 to prime reverse tran-
scription. Increasing amounts of pLEGFP-C1 and pLEGF-
P(Lys,3) were transfected into the EcoPack packaging cell
line and the resultant vector supernatants were titered on
XC cells. Consistent with previous results, we found that
the retroviral vector with a PBS complementary to
tRNALys,3 exhibited approximately 2-fold less transducing
units than did a vector with the wild-type PBS (Fig. 1B).
Lund et al. concluded that MuLV replicates efficiently with
altered PBS sequences with the caveat that the relatively
small differences seen in single-cycle titrations might be
amplified upon serial passaging of replication competent
virus (Lund et al., 1993).
Reversion of PBS-mutated MuLV following extended culture
Since the single-cycle titrations of PBS-mutated MuLV
vectors may obscure the preference of MuLV for
particular tRNA primers, we constructed a replication
competent proviral genome with the PBS made comple-
mentary to tRNALys,3, and propagated infectious virus in
culture. High molecular weight DNA was harvested at
various time points and the PBS region of integrated
Fig. 1. Comparison of single-cycle transduction efficiencies obtained from
pLEGFP-C1 and pLEGFP(Lys,3). (A) Schematic of defective MuLV
proviral genomes. pLEGFP-C1 contains the native PBSPro, whereas
pLEGFP(Lys,3) has a PBS made complementary to tRNALys,3. (B)
Concentration of transducing units in response to increasing amounts of
proviral plasmid. EcoPack packaging cells were transfected with increasing
amounts of either pLEGFP-C1 (filled circles) or pLEGFP(Lys,3) (open
circles). Supernatants from each transfection condition were titered on XC
cells by selecting for G418-resistant colonies. The data are shown as an
average from three independent transfections for each point, with standard
deviations represented by error bars.
M.T. Palmer et al. / Virology 333 (2005) 337–348 339proviruses was amplified by PCR. Where sequencing of
the PCR product showed ambiguity across the PBS, the
product was cloned and individual clones were
sequenced. The population of proviral genomes reflected
the use of tRNALys,3 to day 24 post-culture (Table 1).
Following 36 days in culture, however, the virus
population was using predominately two new PBS
sequences (Table 1). Five of 6 TA clones revealed a
PBS that is identical to the apparent PBS of HERV9
(accession no. AC022068) and HERV17 (e.g. accession no.
AC072023), and that is complementary to a tRNA predicted
to be an isoacceptor of arginine (e.g. accession nos.
AC111186, AC138330 and AC124460). Few second-site
mutations were present, indicating that the change in the
sequence resulted from the aberrant placement of the
tRNAArg isoacceptor on to the non-cognate tRNALys,3-
complementary PBS, followed by the inheritance of the
tRNAArg sequence during plus-strand synthesis. In contrast,
1 of 6 TA clones at day 36 post-culture contained a PBS
complementary to tRNAPro, indicating this virus had a
replication advantage over the starting virus with a PBS
complementary to tRNALys,3. In this case, numerous
second-site mutations were present, which is consistentwith the acquisition of this sequence through recombination
with an endogenous retroviral sequence. Although the
acquisition of a PBS complementary to tRNAGln through
recombination has been reported previously (Colicelli and
Goff, 1986a; Lund et al., 1999; Mikkelsen et al., 1998a,
1998b; Palmer and Morrow, 2004), this is the first report, to
our knowledge, of recombination with one of the numerous
endogenous elements known to contain a tRNAPro-comple-
mentary PBS. The sequence we recovered is similar to
several endogenous sequences deposited in GenBank (e.g.,
accession nos. U63133, AB050720, K02730 and M19118).
By day 48 of culture, we recovered predominantly PBS
sequences complementary to tRNAPro indicating the virus
had a replication advantage over the virus with a PBS
complementary to tRNALys,3.
To determine the reproducibility of these results, we
initiated infection using a second stock of virus generated
by an independent transfection of the p63-2(Lys,3) proviral
clone. As before, the sequence of the PBS changed to
reflect complementarity to the previously identified
tRNAArg isoacceptor (Table 2). In this trial, however,
MuLV continued to use this isoacceptor to day 234 of
culture, at which time the experiment was terminated. This
suggests to us that the recombination event seen in the first
trial occurs with a very low frequency, but that when the
event does occur, the recombinant virus that uses tRNAPro
rapidly outgrows the virus with a PBS complementary to
tRNAArg.
Influence of U5 sequence complementary to anticodon of
tRNALys,3 on PBS stability
HIV-1 RNA contains a stem–loop structure immedi-
ately upstream of the PBS. Previous studies have shown
the importance of the loop sequence in facilitating the use
of the tRNA primer through an interaction with the tRNA
anticodon loop. MuLV, too, is predicted to form a stem–
loop structure in a context similar to that of HIV-1 (Fosse
et al., 1998) (Fig. 2A). However, the loop sequence is not
complementary to the anticodon loop of tRNAPro.
Interestingly, 3 of the bases are complementary to the
anticodon loop of the minor species of tRNAGln, which is
the isoacceptor used to suppress the amber stop codon
that separates the gag and pol. To determine if the loop
sequence of MuLV can influence the selection of the
tRNA primer, we changed the sequence of the loop in
63-2(Lys,3) such that all 4 bases are complementary to
the anticodon loop of tRNALys,3, yielding the p63-
2(Lys,3/Aloop) proviral clone. This mutation is not
predicted to alter the overall RNA structure of the PBS
region (Fig. 2B).
After 27 days in culture, proviral DNAwas amplified and
the PCR product was sequenced directly. The PBS was
identical to the input p63-2(Lys,3/Aloop) sequence (Table
3). The PCR product recovered from integrated proviruses
after 54 days in culture was cloned and 7 individual clones
Table 1
Sequences recovered from the U5 and PBS regions following propagation of 63-2(Lys,3): Trial #1
Sequencea Sampleb Days post-
culture
Lys,3c
CCTCTGAGTGATTGACTACCCGTCAGCGGGGGTCTTTCATT TGGCGCCCGAACAGGGAC CGGGAGACC Input
Lys,3
* * * * * * * * * * *** * * *** * * * ** * * * * * * * * * * **** * *** TGGCGCCCGAACAGGGAC * * * * * * * * * PCR Product 6, 15 and 24
Argd
* * * * * * * * * * *** * * *** * * * ** * * * * * * * * * * **** * *** TGGCGACCACGAAGGGAC * * * * * * * * * 4/6 36
* * * * * * * * * *G** * * *** * * * ** * * * * * * * * ** **** * *** TGGCGACCACGAAGGGAC * * * * * * * * * 1/6 36
Proe
* * * *A* * * *A*** * * **G* * * - -AGT* * * * * ** **** * *** TGGGGGCTCGTCCGGGAT * C* * * * * * * 1/6 36
Pro
* * * *A* * * *A*** * * **G* * * - -AGT* * * * * ** **** * *** TGGGGGCTCGTCCGGGAT * C* * * * * * * PCR Product 48
a Spaces separate the PBS from flanking sequence. Asterisks represent conserved nucleotides.
b Input refers to the p63-2(Lys,3) clone used to initiate infection. PCR products were sequenced directly as indicated. Sequences of cloned PCR products are
shown as frequencies of TA clones analyzed (i.e., number observed over total number analyzed).
c PBS complementary to the 3V terminal 18 nucleotide sequence of tRNALys,3.
d PBS complementary to the 3V terminal 18 nucleotide sequence of a putative isoacceptor of arginine.
e PBS complementary to the 3V terminal 18 nucleotide sequence of tRNAPro.
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One contained sequence consistent with previously
described recombinants (Colicelli and Goff, 1986b; Lund
et al., 1999; Mikkelsen et al., 1998a, 1996; Palmer and
Morrow, 2004) to yield a PBS complementary to tRNAGln.
Four clones contained a PBS complementary to tRNALys1,2.
By day 84, the population of proviral genomes reflected the
essentially exclusive use of tRNALys1,2. The use of this
tRNA persisted out to day 234 of culture. Interestingly, the
base immediately 3V to this PBS had changed from a C to a
T, thereby giving this PBS sequence 19 contiguous bases of
complementarity to tRNALys1,2. Previous work has shown
that tumors induced by an SL3-3 strain of MuLV made to
utilize tRNALys,3 occasionally contained proviruses with a
PBS complementary to tRNALys1,2 (Lund et al., 1999). We
found this pattern with 63-2(Lys,3/Aloop) but not 63-
2(Lys,3), which suggests that alteration of the loop sequence
may influence the selection and use of tRNA primers.Table 2
Sequences recovered from the U5 and PBS regions following propagation of 63-2(Lys,3): Trial #2
Sequencea Sampleb Days post-culture
Lys,3c
CCTCTGAGTGATTGACTACCCGTCAGCGGGGGTCTTTCATT TGGCGCCCGAACAGGGAC CGGGAGACC Input
Lys,3
* * * * * * * * * * *** * * *** * * * ** * * * * * * * * * * **** * *** TGGCGCCCGAACAGGGAC * * * * * * * * * PCR Product 27
Argd
* * * * * * * * * * *** * * *** * * * ** * * * * * * * * * * **** * *** TGGCGACCACGAAGGGAC * * * * * * * * * PCR Product 54, 60, 78, 111,
150, 189, 234
a Spaces separate the PBS from flanking sequence. Asterisks represent conserved nucleotides.
b Input refers to the p63-2(Lys,3) clone used to initiate infection. PCR products were sequenced directly.
c PBS complementary to the 3V terminal 18 nucleotide sequence of tRNALys,3.
d PBS complementary to the 3V terminal 18 nucleotide sequence of a putative isoacceptor of arginine.Replication kinetics of mutant MuLV
The evolution of the PBS sequence during extended
culture implies that each successive change yielded a virus
with improved replication kinetics. To determine the growth
kinetics of these viruses relative to the input viruses, and to
each other, the PBS region of the spontaneously mutated
viruses was subcloned into p63-2. Supernatants from
infected 3T3 cells were normalized for RT activity and used
to infect fresh 3T3 cells. As evidenced by the appearance of
RT activity in the culture supernatants, 63-2(Arg) replicated
more rapidly than did 63-2(Lys,3), and wild-type MuLV
grew more rapidly than did 63-2(Arg) (Fig. 3). These results
mirror the order in which mutant viruses appeared during
extended culture (Table 1) and confirm the preference of
MuLV for tRNAPro. Similarly, 63-2(Lys1,2/Aloop) grew
more rapidly than did 63-2(Lys,3/Aloop) (Fig. 3), corrobo-
rating the evolutionary data presented in Table 3. We next
Fig. 2. Stem–loop structures of the U5-PBS region of retroviral RNA as
predicted by mfold version 3.1 (Zuker, 2003). The nucleotides in grey are
the PBS. Panel (A) Wild-type MuLV sequence (p63-2) was the PBS
complementary to tRNAPro. Panel (B) Wild-type MuLV sequence in which
the PBS has been altered to be complementary to tRNALys,3 (p63-2(Lys,3)).
Additional changes in the loop sequence (changes to adenine, circled)
making it complementary to the anticodon loop of tRNALys,3 are shown.
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wild-type virus. For this analysis, we made use of the XC
plaque assay to determine the infectious units of each virus
relative to the reverse transcriptase activity. We found that
the viruses that use tRNAArg or tRNALys1,2 were approx-
imately 30% and 10% as infectious as the wild-type. The
starting virus designed to use tRNALys,3 was approximately
1% as infectious as wild-type. Interestingly, the virus
engineered with the mutations in U5 and the PBS to facilitate
use of tRNALys,3 was the least infectious. Thus, the inclusion
of the sequences in U5 not only did not facilitate the
selection of tRNALys,3, but concomitantly reduced the
infectivity of the resultant virus. The results of this analysis,
clearly shows though that viruses with a PBS complementary
to tRNAPro have a replication advantage.
Analysis of virion tRNAs
A common feature among several different retroviruses is
the enrichment of a subpopulation of tRNA in virions.
Included within this population is the tRNA primer that is
used for replication. In a previous study, we found that for
HIV-1, even if the virus used tRNAHis rather than tRNALys,3
for replication, the virion particles were still enriched fortRNALys1,2,3 (Zhang et al., 1996). Previous studies have
examined the virion tRNA content for MuLVand did not find
an enrichment of tRNAPro over several other tRNAs
(including tRNAArg and tRNALys) in the virions, although
tRNAPro was the predominant tRNA in association with the
virion RNA (Waters and Mullin, 1977). Recent studies have
shown that the pol gene product forMuLV, in contrast to ALV
and HIV, is not required for the incorporation of tRNA (Fu et
al., 1997). Since the mutant viruses in our study differ by only
the PBS, we wanted to examine how this would affect the
ratios of tRNA in the virions compared to wild-type virus. For
this analysis, we isolated similar amounts of each virus, as
determined by RT value, and following extraction of RNA
probed for tRNAPro, tRNAArg, and tRNALys. We found that
for all viruses analyzed, the relative amounts of each tRNA
were similar. That is, the wild-type virus and the viruses that
had used tRNAArg or tRNALys all had similar amounts of
tRNAPro. tRNAPro is incorporated into the virion even though
the virus uses tRNAArg or tRNALys as the primer. Addition-
ally, the wild-type virus had similar amounts of tRNAArg and
tRNALys as those viruses, which use these tRNAs for primers.
Thus, we did not select for viruses that enriched for different
population of tRNAs (Fig. 5).Discussion
In the current study, we have investigated the stability of
MuLV in which the PBS has been altered to be comple-
mentary to tRNALys,3. Based on our studies with MuLV
vectors and full-length viruses, it is clear that tRNALys,3 can
be selected and used as the replication primer. Upon extended
culture of viruses with a PBS complementary to tRNALys,3,
we noted that the PBS recovered was complementary to
tRNAArg, indicating that the virus was now using this tRNA
as the primer for reverse transcription (Tables 1 and 2). In an
attempt to stabilize the use of tRNALys,3, we made an
additional mutation within U5 in which nucleotides were
substituted in the loop region of a predicted stem–loop to be
complementary to the anticodon of tRNALys,3. Although we
generated a viable virus upon in vitro culture, this virus
adapted to utilize tRNALys1,2 as the primer for reverse
transcription (Table 3). Subsequent analysis of the infectivity
of these viruses revealed that the viruses that utilize tRNAArg
or tRNALys1,2 were approximately 30% and 10%, respec-
tively, as infectious as the wild-type virus, while viruses
which were engineered to utilize tRNALys,3 were approx-
imately 1% as infective as the wild-type virus (Fig. 4).
Finally, comparison of the virion tRNA content of the wild-
type and mutant viruses revealed no substantial difference
with respect to the presence of tRNAPro, tRNAArg or tRNALys
(Fig. 5). The results of these studies suggest a preference for
the selection of tRNAPro by MuLV for high-level replication.
The initiation of retrovirus replication requires the
extension from a cellular tRNA that is positioned at the
PBS (Panet and Berliner, 1978; Peters and Dahlberg, 1979;
Table 3
Sequences recovered from the U5 and PBS regions following propagation of 63-2(Lys,3/Aloop)
Sequencea Sampleb Days post-culture
Lys,3c
CCTCTGAGTGATTGACTACCCGTAAACGGGGGTCTTTCATT TGGCGCCCGAACAGGGAC CGGGAGACC Input
Lys,3
* ***** * * * * **** * *** * * * ** * * * * * * * * * * **** **** TGGCGCCCGAACAGGGAC * * * * * * * * * PCR Product 27
Lys,3
* ***** * * * * **** * *** * * * ** * * * * * * * * * * **** **** TGGCGCCCGAACAGGGAC * * * * * * * * * 2/7 54
Lys1,2d
* ***** * * * * **** * *** * * * ** * * * * * * * * * * **** **** TGGCGCCCAACGTGGGGC * * * * * * * * * 4/7 54
Glne
* ***A* *T* * **** * **** * * - ACCT * * * *A* * **** **** TGGAGGTCCCACCGAGAT TA* * * * * * * 1/7 54
Lys1,2
* ***** * * * * **** * *** * * * ** * * * * * * * * * * **** **** TGGCGCCCAACGTGGGGC T* * * * * * * * PCR Product 84, 111, 153,
189, 234
a Spaces separate the PBS from flanking sequence. Asterisks represent conserved nucleotides. The loop sequence is in bold.
b Input refers to the p63-2(Lys,3/Aloop) clone used to initiate infection. PCR products were sequenced directly as indicated. Sequences of cloned PCR
products are shown as frequencies of TA clones analyzed (i.e., number observed over total number analyzed).
c PBS complementary to the 3V terminal 18 nucleotide sequence of tRNALys,3.
d PBS complementary to the 3V terminal 18 nucleotide sequence of tRNALys1,2.
e PBS complementary to the 3V terminal 18 nucleotide sequence of tRNAGln.
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replication have been elucidated, the mechanism by which
the tRNA is selected from the intracellular milieu and
positioned at the primer-binding site remains unclear. In
particular, how and why a retrovirus selects a specific tRNA
for use as the replication primer is not understood. One way
to explore this question is to generate viruses in which the
PBS has been altered to be complementary to tRNAs otherFig. 3. Kinetics of replication of infectious MuLV with altered PBS and
loop sequences. Cultures were initiated with supernatant stocks containing
equivalent amounts of RT activity. Infected cells were split 1:10 every 3
days. Supernatants were harvested in conjunction with each passage and
analyzed for RT activity over an 18-day period. The data are from parallel
(i.e., duplicate) cultures for each condition and shown as an average for
each time point, with standard deviations represented by error bars. WT;
Arg; Lys1,2/Aloop; Lys,3; and Lys,3/Aloop refer to the genomes of p63-2,
p63-2(Arg), p63-2(Lys1,2/Aloop), p63-2(Lys,3) and p63-2(Lys,3/Aloop),
respectively.than that which is typically used as the primer for reverse
transcription. In a previous study, MuLV were generated
which utilized tRNALys,3 as the replication primer (Lund et
al., 1993, 1999). Consistent with the results of our study,
both MuLV vectors and viruses were generated that could
use tRNALys,3 as a primer. Thus, similar to HIV-1 and ALV,
MuLV has the genetic potential to select and use alternative
tRNA primers for replication. In contrast to the results
presented here though, a previous study reported thatFig. 4. Infectivity of MuLV with altered PBS and loop sequences. The RT-
assayed stocks used to initiate the cultures shown in Fig. 3 were serially
diluted and evaluated for infectious units (IU) by the XC plaque assay
technique. Infectivity was determined by dividing the number of IU by RT
values and is expressed as a percentage of wild-type infectivity. The
identities of the samples are as described in the legend to Fig. 3.
Fig. 5. Northern blot analysis of virion-associated tRNAs. Virion RNAwas
isolated from PBS-mutated MuLV as described in Materials and Methods.
Sample amounts were normalized based on the relative RT values of the
concentrated viruses as measured prior to RNA extraction. Blots were
probed for tRNAPro (Panel A), tRNAArg (Panel B) and tRNALys (Panel C).
The autoradiograms were scanned and the intensities compared to that of
the wild-type (set at 100%). Data presented are representative of two
experiments. The identity of the samples are as described in the legend to
Fig. 3.
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following in vitro culture (Lund et al., 1999). Following in
vivo infection, though analysis of the tumors that arose as a
result of infection with viruses with a PBS complementary
to tRNALys,3 revealed PBS complementary to tRNALys1,2 or
tRNAGln. The results of our current study provide an
important extension to this previous study in that we
demonstrate the evolution of MuLV with a starting PBS
complementary to tRNALys,3 to viruses with a PBS
complementary to tRNALys1,2, tRNAArg or tRNAPro. Thus,
as a result of continued replication, MuLV demonstrated
preference for certain tRNAs to be selected as the primer for
reverse transcription. It is unclear then why the results of the
previous study (Lund et al., 1999) differ from the results
presented in this study. One possibility is that the previous
in vitro studies were not sufficiently long enough to allow
the evolution and emergence of viruses in which the PBS
has been altered to be complementary to tRNALys,3 to either
tRNALys1,2, tRNAArg, or tRNAPro. Most probably, multiple
replication cycles are needed to select for the reversion from
the PBS complementary to tRNALys,3 to a different PBS.
Additional studies will be required to resolve this issue.
The results of our studies withMuLV showmany parallels
with previous studies done in which the PBS of HIV-1 have
been altered so as to use alternative tRNAs. In the case of
HIV-1, alteration of the PBS from the wild-type (comple-
mentary to tRNALys,3) to a variety of other tRNAs resulted in
viruses that could transiently utilize these tRNAs for
initiation of reverse transcription (Das et al., 1995; Li et al.,
1994; Wakefield et al., 1995). However, upon subsequent in
vitro culture, these viruses reverted back to utilize tRNALys,3
as the primer for replication. Previous studies have also
shown that MuLV can also accommodate a variety of tRNA
primers (other than tRNAPro) for initiation of reverse tran-
scription (Lund et al., 1993, 1997, 2000a, 2000b). Most of
these studies were done utilizing an MuLV vector in which a
reporter gene has been substituted for the viral genes that are
supplied in trans from a complementing cell line. In fact,
consistent with the results presented in this study, a similar
level of infectivity (less than 5-fold difference from the wild-
type) was noted for several different MuLV vectors in which
the PBS was altered to be complementary to tRNAs other
than tRNAPro. Thus, similar to HIV-1, MuLV probably has
access to a variety of tRNAs during the selection process.
Why some tRNAs are preferred is unknown. One possibility
is that MuLV has evolved to select certain tRNAs because
they are preferentially incorporated into virions. However,
previous studies have shown a variety of tRNAs, including
tRNAPro, tRNAArg, and tRNALys, are found in MuLV virions
(Waters and Mullin, 1977). Analysis of the wild-type and
mutant viruses in this study demonstrated that the overall
proportions of these tRNAs did not change as a result of the
virus using a tRNA primer other than tRNAPro. Thus, similar
to HIV-1, the presence of the tRNA in the virion does not
necessarily reflect that tRNA selected for initiation of reverse
transcription.
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cases, the virus could stably use alternative tRNAs if
additional mutations within the U5 region were made such
that nucleotides complementary to the anticodon region of
the target tRNA were added within the loop region of a
predicted stem loop (Dupuy et al., 2003; Kang et al., 1997,
1999; Wakefield et al., 1996). A study with MuLV has also
modeled an RNA stem loop region within U5 (Fosse et al.,
1998). However, the nucleotides displayed on the loop
region of this stem loop are not complementary to tRNAPro
but rather are complementary tRNAGln. Interestingly, this
tRNA, has been found to be effectively used by MuLV both
in vitro and in in vivo (Colicelli and Goff, 1986a). Based on
our previous studies with HIV-1, we determined the effect of
altering the loop region of the predicted stem loop in MuLV
to be complementary to the anticodon of tRNALys,3. In
contrast to our studies with HIV-1, the addition of this
nucleotide sequence in the RNA stem loop did not enhance
the ability of the virus to utilize tRNALys,3. Why the virus
reverted to utilize tRNAArg or tRNALys1,2 is not clear. We
have noted for HIV-1, not all loop PBS combinations are
effective in allowing the virus to utilize alternative tRNAs for
initiation of reverse transcription (Kang et al., 1996). In fact,
we have found only a few cases in which the loop PBS
combination results in the virus utilizing alternative tRNAs
stably for initiation of reverse transcription. Thus, although
the selection process for both viruses share a common feature
that complementarity with the PBS is an important determi-
nant for selection, there appears to be differences with
respect to the roles from that regions within U5 play in the
selection process.
Finally, taken in context, the results of our studies with
HIV-1 and MuLV provide a perspective for a complex
process in which the viruses select the tRNA from the
intracellular milieu. Some of this process is governed by
favorable interactions between the tRNA and the viral
genome at the PBS (and U5). Modeling of the U5-PBS
RNA of the wild type genome revealed extensive RNA/
RNA interactions. Two prominent paired regions (loops)
were evident; one of which encompassed the 3V nucleotides
of the PBS and the viral genome (Fig. 6). A similar loop
region has been predicted for the HIV-1 U5-PBS. In a
previous study, we suggested that this exposed RNA loop
region could interact with the TcC loop of the tRNA to
facilitate selection and placement of the tRNA (Yu and
Morrow, 2001). Interestingly, comparison of the similar
region of MuLV with a PBS complementary to tRNALys,3,
tRNALys1,2, and tRNAArg shows a progression of RNA
structures similar to the wild type genome. That is, the virus
with the PBS complementary to tRNALys,3, which had the
poorest replication and an unstable PBS, has the most
predicted disordered RNA structure. Viruses that have PBS
complementary to tRNALys1,2 and tRNAArg have U5-PBS
RNA interactions with more order similar to the wild type;
the virus with a PBS complementary to tRNAArg, which
replicates at a level 30% of the wild type, has the RNAstructure closest to the wild type. Thus, one explanation for
the preference in tRNAArg and tRNALys1,2 would be more
favorable RNA structure around the PBS that facilitates
selection and/or replication. Other intracellular constraints
might also control the selection of particular tRNAs. Most
probably, these constraints reflect the availability of these
tRNAs within the cell. Since most tRNAs are involved with
protein synthesis at any one time, results of studies with
HIV-1 and MuLV suggest that coordination between viral
protein synthesis and primer selection is needed by the
virus to generate infectious virus. In support of this, in a
recent study, we found that tRNA transport from the
nucleus to the cytoplasm and inclusion into the translational
pathway facilitated the selection of the tRNA primer by
MuLV (Kelly et al., 2003). However, the complexity of the
process is highlighted by the fact that even if the tRNA
primer is provided in excess, as in our previous study with
yeast tRNAPhe (Palmer and Morrow, 2004), MuLV
exhibited a preference for certain tRNAs (in this case
tRNAGln). The further use of both the HIV and MuLV
systems to elucidate common features involved in primer
selection should provide the framework to understand the
preference for certain tRNAs in the primer selection
process.Materials and methods
Plasmid construction
pLEGFP-C1 (Clontech, Palo Alto, CA) encodes a MuLV
retroviral vector that expresses green fluorescence protein
and resistance to G418, in lieu of gag/pol and env. The
GeneEditor in vitro site-directed mutagenesis system
(Promega, Madison, Wis.) was used to change the PBS in
pLEGFP-C1 from its native complementarity to tRNAPro to
have a sequence complementary to the 3V terminal 18 nu-
cleotides of tRNALys,3 using the primer 5V-GGCAG
GGGTCTCCAAGTCCCTGTTCGG GCGCCAAAT-
GAAAGACCCC-3V. The resulting plasmid was named
pLEGFP-Lys,3.
p63-2 is an infectious proviral clone of Moloney murine
leukemia virus (Bacheler and Fan, 1981). The 5V end of the
proviral genomewas amplified by PCR using Pfu polymerase
(Stratagene, San Diego, CA) with primers PciIFor (5V-
GCGCGACATGTAAATGAAAGACCCCACCCG-3V) and
BsrGIRev (5V-GGCTTAGGGTG TACAAAGGG-3V). The
product was cloned into pCR4blunt (Invitrogen, Carlsbad,
CA). Mutagenesis was performed using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene) according to the
manufacturer’s instructions. The PBS sequence was changed
from complementarity to tRNAPro to complementarity to
tRNALys,3 using the primers 5V-AGCGGGGGTCTTTCQ
ATTTGGCGCCCGAACAGGGACCGGGAGACCCC-
TGC-3V and 5V-TGGGCAGGGGTCTCCCGGTCCCTGTTQ
CGGGCGCCAAATGAAAGACCCCC-3 V to yield
Fig. 6. RNA modeling of U5-PBS of wild type and mutants. Panel (A) Predicted RNA structure of a region of the U5-PBS from the wild type genome. The
PBS, complementary to tRNAPro is shown in grey (p63-2). Panel (B) Predicted RNA structure of the U5-PBS of MuLV with a PBS complementary to tRNAArg
(p63-2(Arg)). The PBS, in grey, was substituted for the wild type PBS so as to maintain the RNA structure similar to that for the wild type. Panel (C) Predicted
RNA structure of the U5-PBS for MuLV with a PBS complementary to tRNALys,3. The PBS, in grey, complementary to tRNALys,3 was substituted for the wild
type. Note the disorder of the 3V region of the PBS compared to wild type (Panel A). Panel (D). Predicted RNA structure of a region of the U5-PBS from the
virus that uses tRNALys1,2 (p63-2(Lys1,2)). The PBS, in grey, complementary to tRNALys1,2 was substituted for the wild type sequence. The base pairs
complementary to the tRNALys,3 anticodon (Fig. 2B) are not shown. Note that two structures can be predicted for the 3V nucleotides of the PBS that are
dependent upon a two-base adenine bulge. The RNA structure with the adenine bulge more closely resembles that for the wild type genome (Panel A).
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into p63-2 to yield p63-2(Lys,3). The U5 loop sequence of
pCR4blunt(Lys,3) was changed using the primers 5V-CTG
AGTGATTGACTACCCGTAAACGGGGGTCTTTCATQ
TTGG-3V and 5V-CCAAATGAAAGACCCCCGTTTACGQ
GGTAGTCAATCACTCAG-3V. The PciI/BsrGI fragment
was subcloned into p63-2 to yield p63-2(Lys,3/Aloop).
p63-2(Arg) and p63-2(Lys1,2/Aloop) are infectious proviral
clones which contain a PBS complementary to a putative
tRNAArg isoacceptor and to a PBS complementary to
tRNALys1,2 with an engineered loop sequence, respectively.
Each was constructed by subcloning the XmaI/AatII frag-
ment from an appropriate TA clone (see below) to the
pCR4blunt transfer vector, with the PciI/BsrGI fragment of
the recombinant transfer vector subsequently cloned into
p63-2.Cell culture, transfection, and vector titration
EcoPack2-293 cells were obtained from Clontech. Unin-
fected cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 1% antibiotic-anti-
mycotic and 10% fetal bovine serum. Transfections and
vector titrations were performed as described previously
(Kelly et al., 2003). For all transfections, cells were rinsed
two times the following day with complete DMEM and
samples were collected on the second day.
Propagation of infectious virus
Infectious virus was produced by PEI-mediated trans-
fection of 293T cells with proviral plasmid DNA. The day
following transfection the medium was replaced with fresh
M.T. Palmer et al. / Virology 333 (2005) 337–348346medium lacking amphotericin B. Twenty-four hours later,
supernatant was diluted 1:1000 in fresh medium lacking
amphotericin B with 8 Ag/mL polybrene, passed through a
0.45 AM filter and used to infect 3T3 cells seeded the
previous day at 10% confluence. The medium was
replaced with fresh medium the next day. Infected cells
were split 1:10 every 3 days. A semi-quantitative
competitive PCR performed under low-stringency condi-
tions (Caballero et al., 1995) was used to monitor infection
during long-term culturing (see below for PCR conditions).
When the cells were significantly infected, the virus was
passaged cell-free following a 1:1000 dilution as described
above.
Sequencing of PBS in proviral DNA
High-molecular weight DNA was isolated from infected
cells by using the Wizard genomic DNA purification kit
according to the manufacturer’s (Promega) instructions.
PCR was used to amplify the PBS region with Taq
polymerase (Invitrogen) using the previously described
primers (Palmer and Morrow, 2004). The thermocycling
parameters included 36 cycles consisting of denaturation
at 94 8C for 1 min, primer annealing at 59 8C for 1 min,
and extension at 72 8C for 50 s. The 530-bp PCR product
was gel extracted. The reverse primer was used to
sequence either the PCR product directly or clones of
the PCR product ligated into the pGEM-T Easy vector
(Promega).
Analysis of viral growth kinetics
To measure the growth kinetics of the mutant viruses,
viruses were propagated as described above except that
the initial infections were performed using supernatents
taken from infected 3T3 producer cells and were
normalized for reverse transcriptase (RT) activity by
taking the average of triplicate measurements. The
infections were performed in duplicate. In conjunction
with each passage, supernatants were harvested every 3
days, clarified by centrifugation (5 min at 7500  g) and
stored as aliquots at 20 8C to be assayed later for RT
activity. The assay was performed as described previously
(Telesnitsky et al., 1995) with the following changes.
Following incubation at 37 8C, reactions were applied to
the Biodyne B membrane of a Silent Screen Plate (Nalge
Nunc Int., Naperville, IL) with a Silent Screen Vacuum
Manifold (Nunc). Plates were washed with 2 standard
saline citrate (SSC) buffer two times with 300 AL per
well. The membrane was removed and rinsed two more
times, 10 min each rinse, with 2 SSC buffer in a dish on
an orbital shaker. The membrane was rinsed in ethanol
and allowed to dry. The Biodyne membrane retains the
impression of the wells, which permitted the signals to be
accurately cut away from each other and measured by
scintillation counting.Analysis of viral infectivity
An XC plaque assay was used to measure infectious units
essentially as described before (Watanabe et al., 1982). The
methylcellulose overlays used in our studieswere prepared by
diluting a stock solution (R&D Systems) 5-fold in complete
DMEM, to a final concentration of 10% FBS and 1%
antibiotics. The viruses used for the analysis of infectivity
were derived from the same supernatant stocks that had been
assayed forRTandused to initiate infections for comparisonof
growth kinetics. Infectivity was determined by dividing
infectious units by RT values.
Virion tRNA isolation and analysis
Supernatants were collected from 3T3 producer cells,
including mock-infected 3T3 cells, clarified by low-speed
centrifugation and passed through 0.45 AM filters. Virus
particles were pelleted over a 20% sucrose cushion (20,000
rpm, 16 h, SW28 rotor) and suspended in serum-free
DMEM. Dilutions of virion suspensions were assayed for
RT activity as described above. Virion RNA was harvested
by phenol/chloroform extraction, precipitated with isopro-
panol/ammonium acetate and suspended in RNase-free
water. Samples were analyzed by Northern blotting as
described before (Palmer and Morrow, 2004) where the
sample amounts were adjusted based on the RT values of
the virion suspensions from which the RNA was derived.
Additional probes used in the present study were specific for
tRNALys1 ,2 (5 V-AACGTGGGGCTCGAACCCAC-
GACCCTGGGATTAAGAGTCCCATGCTCTACCGACT-
GAGCTAG-3V) and tRNAArg (5V-GCCAGC CAGGAGTQ
CGAACCTAGAATCTTCTGATCCGCAGTCAGACGCGQ
TTATCCATTGC-3V).
Computer analyses
Proviral sequences recovered from extended culturing
were analyzed using ClustalX version 1.5b. Retroviral RNA
secondary structures were predicted by free-energy mini-
mization using the mfold software available at http://
www.bioinfo.rpi.edu/applications/mfold (Zuker, 2003). The
BLAST service provided by the NCBI (National Center for
Biotechnology Information) was used to identify sequences
deposited in GenBank that show similarity to those
recovered in this study.Acknowledgments
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